ASCO Registry

This page was last updated on 5/18/2020. Please check back frequently for updates.

The American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry (ASCO Registry) aims to help the cancer community learn more about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The ASCO Registry is designed to collect both baseline and follow-up data on how the virus impacts cancer care and cancer patient outcomes during the COVID-19 pandemic and into 2021.

Sample Data Collection Forms

 

ASCO will deliver periodic reports with key findings so that the oncology community has real-time information to help inform treatment approaches for patients with cancer who have a confirmed COVID-19 infection. The reports will allow practices to easily and confidently share information on COVID-19 infections among their patients.

Data from participating practices will be collected and securely stored on the CancerLinQ® platform.  

Who is eligible?

The registry is open to all U.S. oncology practices, including physician-owned, academic, and hospital/health system-owned practices, and hospitals (regardless of whether cancer specific). ASCO plans to make funding available to practices to help cover research data-entry costs.

ASCO Registry Acceptable for MIPS Improvement Activity

ASCO’s Survey on COVID-19 in Oncology Registry (ASCO Registry) is an acceptable clinical trial registry for the attestation of the high-weighted practice Improvement Activity (IA), “COVID-19 Clinical Trials related to the Emergency Response & Preparedness,” under the Merit-based Incentive Payment System (MIPS).

All oncology practices are encouraged to participate. The following practices have enrolled in the ASCO Registry. 

  • AIS - Cancer Center - Bakersfield (Bakersfield, CA)
  • Baptist Clinical Research Institute (Memphis, TN)
  • The Cancer Team - Bellin Health (Green Bay, WI)
  • CarolinaEast Medical Center (New Bern, NC)
  • Fox Chase Cancer Center (Philadelphia, PA)
  • Gene Upshaw Memorial Tahoe Forest Cancer Center (Truckee, CA)
  • Good Samaritan Hospital (Corvallis, OR)
  • Goshen Center for Cancer Care (Goshen, IN)
  • Great Lakes Cancer Management Specialist (Grosse Pointe Woods, MI)
  • Greater Baltimore Medical Center (Baltimore, MD)
  • Hematology Oncology Associates of Central New York (East Syracuse, NY)
  • Illinois Cancer Care (Peoria, IL)
  • Levine Cancer Institute, Atrium Health (Charlotte, North Carolina)
  • Oncology Hematology Care, Inc. (Cincinnati, Ohio)
  • Penn Medicine Lancaster General Health - Ann B Barshinger Cancer Institute (Lancaster, PA)
  • Penn Medicine Princeton Oncology (Plainsboro, NJ)
  • Tufts Medical Center (Boston, MA)
  • University of Kansas Medical Center (Kansas City, KS)
  • Virginia Cancer Specialists (Alexandria, Virginia)

The registry collects data about patients undergoing cancer treatment who have a confirmed prior or current COVID-19 infection. Specifically, the registry will collect data about patients with cancer and patients who are cancer-free receiving adjuvant cancer therapy within a year of cancer surgery, including patients receiving hormone-only adjuvant therapy and patients receiving supportive care only.

How do we enroll our practice? 

Click on “Enroll Your Practice” tenter your practice information and access the research and data use agreementAfter reviewing the protocol schema, research and data use agreement, and central Institutional Review Board (IRB) exemption letter, interested practices should submit the completed research and data use agreement to CENTRA@asco.org. Once the research and data use agreement is executed, ASCO will provide the Registry website link for data entry.  

From that point, practices will: 

  • Enter initial data on patients with cancer who have confirmed COVID-19 disease. Required data includes:
    • Limited patient identifying data, including home zip code, date of birth, gender, race, ethnicity, type of cancer, and comorbidities 
    • COVID-19 status, including symptoms, treatments, and outcomes 
    • Current cancer status, including treatment plans, any changes to treatment plans, and response to treatments 
  • Provide any follow-up patient data on COVID-19 and cancer outcomes (ideally on a weekly or biweekly basis, but at least once per month) over an 18-month period. 

ASCO will list participating practices on the ASCO Registry website. Practices may withdraw from the registry at any time. 

Please contact CENTRA@asco.org for additional information or questions. 

 

Acknowledgements

ASCO is grateful for the timely and thorough input from our Cancer Research Committee (CRC) and Research Community Forum (RCF) leadership on who advised on key elements of the ASCO Registry.

  • R. Donald Harvey III, PharmD, FCCP, FHOPA; Winship Cancer Institute at Emory University (Atlanta, GA)
    • Chair, ASCO CRC
  • Edward S. Kim, MD, FACP, FASCO ; Levine Cancer Institute, Atrium Health (Charlotte, NC)
    • Immediate Past-Chair, ASCO RCF
  • Heidi D. Klepin, MD, MS; Wake Forest Baptist Health (Winston-Salem, NC)
    • Immediate Past Chair, ASCO CRC
  • Abdul-Rahman Jazieh, MD, MPH; King Abdulaziz Medical City, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center (Riyadh, Saudi Arabia)
    • Immediate Past-Chair, ASCO International Affairs Committee
  • Kathryn F. Mileham, MD, FACP; Levine Cancer Institute, Atrium Health (Charlotte, NC)
    • Chair-Elect, ASCO CRC
  • Grzegorz S. Nowakowski, MD; Mayo Clinic (Rochester, MN)
    • Chair-Elect, ASCO RCF
  • Alexander I. Spira, MD, PhD, FACP; Virginia Cancer Specialists (Alexandria, VA)
    • Member, ASCO CRC
  • Jaap Verweij, MD, PhD, FASCO; Erasmus University (Rotterdam, Netherlands)
    • ASCO Board Liaison, ASCO CRC
  • David M. Waterhouse, MD, MPH; Oncology Hematology Care, Inc. (Cincinnati, OH)
    • Chair, ASCO RCF